ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 540

Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors

Christopher Tracy1, Jess Edison2, S. Frattalone2 and C. Moratz3, 1Internal Medicine-Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 2Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 3Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: mouse model and treatment, SLE, T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure.   The pathogenesis is characterized by complex immune dysfunction, including aberrant T-cell responses.   FTY720, an FDA approved therapy for multiple sclerosis (MS), is a compound with the ability to modulate T-cell proliferation through S1P receptors.  The aim of this study is to attenuate tissue injury and define a subset of S1P receptors and expression patterns that may be altered in the autoimmune prone ischemic reperfusion injury (IRI) mouse model.

Methods: Immune competent (C57BL/6) and autoimmune prone (B6.MRL/lpr) mice were exposed to FTY720 or Pertussis toxin followed by superior mesenteric artery ischemic reperfusion injury.  Histological analysis of tissue samples was performed to assess tissue injury and the extent of inflammatory cell infiltration into the injured tissues.  Multiplex array based cytokine analysis and immunohistochemistry analysis of isolated tissue lysates established and confirmed the extent of induction of inflammatory cytokine production.  Immunofluorescence staining of tissue samples defined specific S1P receptor expression patterns.

Results: Targeting S1P receptors with FTY720 attenuates tissue injury in the autoimmune prone mice (B6.MRL/lpr) compared to the immune competent controls (C57BL/6).   Multi-ligand targeting the S1P receptors decreased T-cell infiltration, IL-6 and IL1B levels in the autoimmune prone mice compared to the immune competent controls.  Immunofluorescence staining of specific S1P receptors showed increased S1P1, S1P2 and S1P3 expression patterns in the autoimmune prone mice compared to the immune competent controls after ischemic reperfusion injury.

Conclusion: These findings support the hypothesis that S1P receptor interaction is a key regulator of T-cell mediated tissue injury and represents a novel therapeutic target in SLE.  The role of specific S1P receptors in the pathophysiology of tissue injury is highlighted by the increased expression patterns of targeted S1P receptors after ischemic reperfusion injury in autoimmune prone mice.   Defining S1P receptor expression in human lupus and how this expression influences the cell responsiveness during states of inflammation warrants further investigation.


Disclosure:

C. Tracy,
None;

J. Edison,
None;

S. Frattalone,
None;

C. Moratz,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploration-of-a-novel-therapeutic-target-in-a-murine-model-of-systemic-lupus-erythematosus-targeting-sphingosine-1-phosphate-s1p-receptors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology